Your browser doesn't support javascript.
Extracorporeal blood purification treatment options for COVID-19: The role of immunoadsorption.
Yigenoglu, Tugçe Nur; Ulas, Turgay; Dal, Mehmet Sinan; Korkmaz, Serdal; Erkurt, Mehmet Ali; Altuntas, Fevzi.
  • Yigenoglu TN; University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Hematology & Apheresis Unit, Ankara, Turkey.
  • Ulas T; Near East University, School of Medicine, Department of Internal Medicine, Division of Hematology, Nicosia, Cyprus.
  • Dal MS; University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Hematology & Apheresis Unit, Ankara, Turkey.
  • Korkmaz S; University of Health Sciences, Kayseri Training and Research Hospital, Department of Hematology & Apheresis Unit, Kayseri, Turkey.
  • Erkurt MA; Inönü University, School of Medicine, Department of Internal Medicine, Division of Hematology & Apheresis Unit, Malatya, Turkey.
  • Altuntas F; University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Hematology & Apheresis Unit, Ankara, Turkey; Ankara Yildirim Beyazit University, School of Medicine, Department of Internal Medicine, Division of Hematology, Ankara, Turkey. Electronic address: faltuntas
Transfus Apher Sci ; 59(4): 102855, 2020 Aug.
Article in English | MEDLINE | ID: covidwho-613576
ABSTRACT
The activation of the innate and adaptive immune systems by SARS-CoV-2 causes the release of several inflammatory cytokines, including IL-6. The inflammatory hypercytokinemia causes immunopathological changes in the lungs including vascular leakage, and alveolar edema. As a result of these changes in the lungs, hypoxia and acute respiratory distress syndrome occur in patients with COVID-19. Even though there are clinical trials on the development of therapeutics and vaccines, there are currently no licensed vaccines or therapeutics for COVID-19. Pharmacological approaches have shown poor results in sepsis-like syndromes caused by the hypercytokinemia. Suppressing the cytokine storm is an important way to prevent the organ damage in patients with COVID-19. Extracorporeal blood purification could be proposed as an adjunctive therapy for sepsis, aiming to control the associated dysregulation of the immune system, which is known to protect organ functions. Several extracorporeal blood purification therapies are now available, and most of them target endotoxins and/or the cytokines and aim improving the immune response. For this purpose, plasmapheresis and immunoadsorption may be an important adjunctive treatment option to manage the complications caused by cytokine storm in critically ill patients with COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Plasmapheresis / Coronavirus Infections / Extracorporeal Circulation / Pandemics / Betacoronavirus Type of study: Prognostic study Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Transfus Apher Sci Journal subject: Hematology Year: 2020 Document Type: Article Affiliation country: J.transci.2020.102855

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Plasmapheresis / Coronavirus Infections / Extracorporeal Circulation / Pandemics / Betacoronavirus Type of study: Prognostic study Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Transfus Apher Sci Journal subject: Hematology Year: 2020 Document Type: Article Affiliation country: J.transci.2020.102855